← All trials
NCT06084663
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2023
- Primary completion
- Feb 25, 2023
- Completion date
- Apr 25, 2023
- First posted
- Oct 16, 2023
- Last posted
- Dec 13, 2023
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Humanis Saglık Anonim SirketiLead sponsor
- Humanis Saglık Anonim SirketiStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.